Lactate Dehydrogenase-to-Albumin Ratio and Adverse Outcomes in HFrEF and HFmrEF Patients

A retrospective cohort study of 1,084 hospitalized patients with heart failure with reduced or mildly reduced ejection fraction. The data, authored by Yaping Zhang and last updated in April 2026, investigates the association between the lactate dehydrogenase-to-albumin ratio and adverse clinical outcomes over a mean follow-up of 29.3 months.

Use Cases

• Predicting heart failure-related readmission risk based on the lactate dehydrogenase-to-albumin ratio.
• Modeling all-cause mortality risk in heart failure patients using biomarker ratios.
• Assessing the incremental predictive value of a new biomarker for composite clinical endpoints.
• Conducting subgroup and sensitivity analyses to validate clinical findings.

Strengths

• Includes data from 1,084 patients, providing a substantial clinical cohort.
• Features a mean follow-up period of 29.3 months for longitudinal outcome tracking.
• Analyses are supported by multiple statistical methods, including Cox regression and Fine-Gray models.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is contained in a 12.3 KB DOCX file, suggesting limited raw data or a summary table format.

Provenance

Source

figshare

Collection Method

Retrospective cohort study of hospitalized patients.

Time Range

Mean follow-up of 29.3 months.

Freshness

Last updated 2026-04-27 10:39:32; freshness should be verified.

Geography

null